NEW ORLEANS--(BUSINESS WIRE)--Vektor Medical, developer of vMap® — the world’s first FDA-cleared technology to localize arrhythmias from just 12-lead ECG data — will present complex case studies that expand vMap’s utility at the Annual American College of Cardiology (ACC) Scientific Session held March 4-6, 2023 in New Orleans.
The two complex clinical case studies being presented by Gordon Ho M.D., UC San Diego Health, highlight the use of vMap to guide the successful cryoablation of PVCs near the intramural anomalous coronary artery and concomitant surgical ventricular tachycardia (VT) and ventricular fibrillation (VF) ablation during left ventricular assist device (LVAD) implantation. The new results add to the growing body of evidence that demonstrates vMap’s utility for the successful treatment of a wide range of arrhythmias, including surgical ablation.
These cases highlight the ability of non-invasive, rapid mapping capabilities to efficiently identify arrhythmia sources and guide ablation during complex cases. vMap guided the successful intra-operative PVC cryoablation during coronary artery unroofing surgery for the treatment of PVCs originating near an intramural anomalous coronary artery. Using pre-procedural automated 12-lead ECG data, vMap successfully guided concomitant surgical VT and VF ablations during LVAD implantation for a patient with end-stage systolic heart failure.
“We are excited to share the latest data showcasing vMap’s remarkable ability to advance cardiac care and provide valuable insights for a wide range of arrhythmia treatments. Our innovative technology has enabled pre-operative mapping of VT and VF using only 12-lead ECG information during surgical ablation, expanding the possibilities for effective treatment,” said Rob Krummen, CEO. “vMap is paving the way with new and improved applications in cardiac arrhythmia mapping. We are committed to continuing our efforts to revolutionize cardiac care, pushing boundaries, and delivering better outcomes for patients.”
Additionally, David Krummen M.D., UC San Diego Health, will present findings from the study, Clinical Impact of Forward-Solution ECG Mapping on Procedure Duration and Fluoroscopy Use During Catheter Ablation Procedures, a time study demonstrating a significant reduction in total procedural duration, mapping duration, and fluoroscopy use after implementation of vMap. These results build on the clinical validation study, The VMAP Study, which was recently published in Circulation: Arrhythmia and Electrophysiology.
The retrospective, case-controlled study evaluated the hypothesis that non-invasive computational ECG mapping reduces overall procedure time, fluoroscopy use, and cost in the EP lab setting. In the study, which included complex cases such as VT and recurrent AF, vMap exhibited:
- 26.1% reduction in procedure time (227±53 vs 307±71 minutes, p<0.001)
- 21.4% reduction in mapping time (127±44 vs 161±48 min, p=0.002)
- 46% reduction in fluoroscopy time (18.1±13.4 vs 33.5±15.1 min, p<0.001)
Vektor’s vMap technology aims to improve first-pass ablation success, lower risks from invasive mapping and long fluoro exposure, and reduce procedure times, all of which are expected to reduce healthcare costs associated with ablation.
vMap is designed to quickly, easily, and non-invasively map arrhythmia sources associated with focal or fibrillation- type arrhythmias in all cardiac chambers, septum, and outflow tracts. The system takes less than three minutes for a clinician to input case information, upload, and markup an ECG, and receive a 3D interactive arrhythmia source location map visualizing the inside and outside of the heart.
About Vektor Medical
San Diego-based Vektor Medical, Inc. is the developer of the world’s first technology to rapidly identify arrhythmia source locations using only 12-lead ECG data. This data is analyzed using proprietary computational modeling to create actionable 2D and 3D cardiac hot spots for the whole heart. The company’s smart, simple, and non-invasive cardiac arrhythmia mapping platform aims to improve first-pass ablation success, lower risks from invasive mapping and long fluoro exposure, and reduce procedure times, all of which are expected to reduce healthcare costs associated with ablation.